ArticleFrontiers in neurology
Hyperhomocysteinemia promotes lipid deposition in skeletal muscle.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lipid storage myopathy (LSM) is characterized by abnormal lipid accumulation in skeletal muscle. Emerging evidence suggests that environmental factors, including the use of antidepressants such as sertraline, may trigger LSM. Given the established link between hyperhomocysteinemia (HHcy) and disrupted lipid metabolism, we investigated its potential role in skeletal muscle lipid deposition. Methods: We enrolled six patients with HHcy undergoing muscle biopsy and explored their clinical and pathological characteristics of skeletal muscle. The mechanistic link was explored in muscle tissues from patients through transcriptomic profiling, quantitative real-time polymerase chain reaction (qRT-PCR), western blotting, and enzymatic assays, and validated in C2C12 myotubes. Results: Four of the six patients presented with clinical myopathic manifestations, including progressive muscle weakness and exercise intolerance, which resolved completely after B-vitamin supplementation, while abnormal skeletal muscle lipid deposition was observed in all six patients. Transcriptome and qRT-PCR analyses demonstrated a significant upregulation of the acetyl-CoA carboxylase β ( Conclusion: This study indicates that HHcy is closely associated with abnormal skeletal muscle lipid deposition. HHcy may correlate with increased ACC2 expression, which elevates malonyl-CoA levels. This, in turn, suppresses CPT1 activity and facilitates abnormal lipid accumulation in skeletal muscle.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.